WinstonWınston
Back
Arcoma AB logo

Arcoma AB

ARCOMA.ST
40
Medical - Devices · Healthcare
Price
kr 8.10
-0.38 (-4.48%)
Market Cap
kr 115.9M
Exchange
Stockholm Stock Exchange
Winston Score
40
Winston is serious
Mixed quality — meaningful strengths and weaknesses.
Data as of Aug 23, 2026 · filings through Jun 30, 2026
How the score breaks down
Quality
Weak
Growth
Weak
Cash Flow
Strong
Stability
Good
Valuation
Strong

Share count rising — dilution

+10.6% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 12.9M (2021) → 14.3M (2025)

Winston Score History

The full picture

Arcoma AB is a Swedish company that makes X-ray imaging systems used in hospitals and clinics. Its core products are digital radiography rooms — the large machines that take X-ray pictures of patients — sold mainly to healthcare providers across Europe. The company has been building medical imaging equipment for decades and focuses specifically on fixed, room-based X-ray systems rather than portable devices.

Arcoma earns money by selling its imaging systems directly to hospitals and through distribution partners, with additional revenue from service contracts and spare parts. It operates primarily in Europe, with Sweden as its home base, and generates roughly $50–60 million in annual revenue, making it a small player in the global medical imaging market dominated by much larger companies like Siemens and Philips. Its main competitive challenge is competing on price and technology against those giants, while its growth opportunity lies in hospital equipment upgrade cycles and expanding its distributor network into new European markets.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
0.5%
Thin — 0.5% gross margin
Profit after running costs
Operating Margin
2.0%
Thin — 2.0% operating margin
Return on the money invested
ROCE
8.4%
Below par — 8.4% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-5.7%
Shrinking sales (-5.7% YoY)
Profit growth
EPS YoY
-25.6%
Earnings shrinking (-25.6% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is
EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
278%
Turns 278% of profit into real cash
Spare cash per sale
FCF Margin
7.6%
Modest free cash flow (7.6%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
236.41x
Comfortably covers interest (236.4x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
28.3x
Growth-priced — P/E 28.3

P/E above the market average. People are paying up for expected growth.

Cheaper or dearer next year
P/E vs Forward
+13.5
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (28.3 → 14.8)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial